| Literature DB >> 33223219 |
Anna M Perrone1, Giulia Dondi2, Susanna Giunchi3, Eugenia De Crescenzo3, Safia Boussedra3, Marco Tesei2, Rocco D'Andrea4, Antonio De Leo5, Claudio Zamagni6, Alessio G Morganti7, Alessandra De Palma8, Pierandrea De Iaco2.
Abstract
INTRODUCTION: During the SARS-CoV-2 pandemic, the majority of healthcare resources of the affected Italian regions were allocated to COVID-19 patients. Due to lack of resources and high risk of death, most cancer patients have been shifted to non-surgical treatments. The following reports our experience of a Gynaecologic Oncology Unit's reallocation of resources in a COVID-19 free surgical oncologic hub in order to guarantee standard quality of surgical activities.Entities:
Keywords: Allocation resources; COVID-19; Gynaecological cancers; Ovarian cancer; Pandemic; SARS-CoV-2
Mesh:
Year: 2020 PMID: 33223219 PMCID: PMC7832928 DOI: 10.1016/j.ygyno.2020.09.030
Source DB: PubMed Journal: Gynecol Oncol ISSN: 0090-8258 Impact factor: 5.482
Fig. 1Epidemiological data about COVID-19 infection in Italy (Fig. 1A) and In Emilia Romagna Region (Fig. 1B).
Legend: The black lines delimit the lockdown period, while the red line indicates the data of the allocation at the COVID-19 free oncologic surgical hub. Hospitalization: number of patients infected with symptoms in the hospitals; ICU: number of admitted in intensive care units; quarantined: subjects isolated for proven or suspected COVID-19 infection; discharged/recovered: number of patients with previous COVID-19 infection; deaths: number of patients dead of COVID-19; sum of positives: total number of infected subject. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Patients' characteristics. General, anesthesiologic and post-operative parameters of the patients scheduled for surgery.
| Variables | Data |
|---|---|
| All patients | 51 |
| General Parameters | |
| Age, years | 58 (± 11.5) |
| BMI | 25.2 (± 5.5) |
| ECOG Performance Status | |
| Grade 0 | 25 (49%) |
| Grade 1 | 18 (35%) |
| Grade 2 | 8 (16%) |
| Grade 3–4-5 | 0 (0%) |
| Residence | |
| Bologna | 19 (37%) |
| Emilia-Romagna | 15 (29%) |
| Extra-region | 10 (20%) |
| Red Zones | 7 (14%) |
| Anesthesiological parameters | |
| ASA Physical Status Classification System | |
| Grade 1 | 1 (2%) |
| Grade 2 | 44 (86%) |
| Grade 3 | 6 (12%) |
| Grade 4–5 | 0 (0%) |
| Epidural analgesia | |
| Yes | 26 (51%) |
| No | 25 (49%) |
| Use of Amines | |
| Yes | 5 (10%) |
| No | 46 (90%) |
| Intensive care admission | |
| Yes | 13 (25%) |
| No | 38 (75%) |
| Possum Score | |
| Possum mortality | 7.5 ± (8.9) |
| Possum morbidity | 31.7 ± 20.7 |
| Physiological score | 16 (± 2.6) |
| Operative severity score | 13 (± 5.1) |
| Post-operative parameters | |
| Clavien-Dindo Classification | |
| Grade 0 | 34 (67%) |
| Grade I | 5 (10%) |
| Grade II | 9 (17%) |
| Grade IIIa | 2 (4%) |
| Grade IIIb | 1 (2%) |
| Grade IV-V | 0 (0%) |
| Blood transfusions | |
| Yes | 11 (22%) |
| No | 40 (78%) |
| Hospital stay, days | 6 ± (4.2) |
Surgical parameters in patients with ovarian and endometrial cancer.
| Variables | Ovarian Cancer | Endometrial Cancer | ||
|---|---|---|---|---|
| n | % | n | % | |
| 23 | 100 | 16 | 100 | |
| 21/23 | 91 | 16/16 | 100 | |
| Up-front Surgery | 14/21 | 67 | 15/16 | 94 |
| Interval Debulking Surgery | 7/21 | 33 | 1/16 | 6 |
| After 3–4 cycles of chemotherapy | 4/7 | 57 | 0/16 | 0 |
| After 6 cycles of chemotherapy | 3/7 | 43 | 1/16 | 6 |
| 2/23 | 9 | 0/16 | 0 | |
| 11/23 | 48 | 15/16 | 94 | |
| Intermediate (4–7) | 11/23 | 48 | 1/16 | 6 |
| 1/23 | 4 | 0/16 | 0 | |
| Laparoscopic surgery | 2/23 | 9 | 14/16 | 88 |
| Diagnostic Laparoscopy for operability | 3/23 | 13 | 0/16 | 0 |
| Diagnostic Laparoscopy + laparotomic surgery | 14/23 | 61 | 0/16 | 0 |
| Laparotomic surgery | 4/23 | 17 | 2/16 | 12 |
| CC-0 (no macroscopic residual disease) | 16/23 | 70 | 16/16 | 100 |
| CC-1 (residual disease <2.5 mm) | 1/23 | 4 | 0 | 0 |
| CC-2 (residual disease >2.5 mm and < 25 mm) | 6/23 | 26 | 0 | 0 |
| CC-3 (residual disease >25 mm) | 0/23 | 0 | 0 | 0 |
| I | 5/23 | 22 | 15/16 | 94 |
| II | 0/23 | 0 | 0/16 | 0 |
| III | 18/23 | 78 | 1/16 | 6 |
| IV | 0/23 | 0 | 0/16 | 0 |
Fig. 2Results of the questionnaire filled by patients admitted to COVID-19 free oncologic surgical Hub. The graphic reports the percentage of patients' acceptance of the newpath. Legend: numbers represent the 12 items of the questionnaire. Blue lines represent the percentage of negative answers, red lines represent the percentage of positive answers. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.
Fig. 3Oncological activity of the Gynaecologic Oncolgy Unit from March 9th to May 4th in 2018, 2019, 2020.Legend: CC: cervical cancer, EC: endometrial cancer, OC:ovarian cancer, VC: vulvar cancer, Sarc: sarcomas, CHT: chemotherapy, RT: radiotherapy, th: therapies.